Tumeurs épithéliales thymiques : biomarqueurs prédictifs et thérapies ciblées

[1]  G. Giaccone,et al.  Phase II study of cixutumumab (IMC-A12) in thymic malignancies. , 2012 .

[2]  N. Girard.  Chemotherapy and targeted agents for thymic malignancies , 2012, Expert review of anticancer therapy.

[3]  P. V. Van Schil,et al.  The Masaoka-Koga Stage Classification for Thymic Malignancies: Clarification and Definition of Terms , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  G. Giaccone,et al.  Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Girard.  Thymic Tumors: Relevant Molecular Data in the Clinic , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  N. Girard,et al.  Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas , 2009, Clinical Cancer Research.

[7]  N. Girard,et al.  Thymoma: a focus on current therapeutic management. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  W. Timens,et al.  Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. , 2008, European journal of cancer.

[9]  K. Kondo,et al.  Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. , 2003, The Annals of thoracic surgery.